CCM
PEAR

CAAS Capital Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

CAAS Capital Management’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,000
Closed -$249K – 1130
2021
Q3 		$249K Buy
+25,000
New +$247K 0.01% 717

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

CAAS Capital Management's PEAR Position: Q4 2021 in Review

CAAS Capital Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2021, closing a stake of 25,000 shares — an estimated $249K sold.

CAAS Capital Management first reported a position in PEAR in Q3 2021 and held it in 1 quarter. The position peaked at $249K in Q3 2021. 25 funds tracked by Wall St. Rank hold PEAR as of Q4 2021.

  • CAAS Capital Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 25,000 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2021, an estimated $249K.
  • CAAS Capital Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2021 and held it in 1 quarter.
  • CAAS Capital Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $249K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.